Alexion pharmaceuticals inc stock price

Alexion Pharmaceuticals, Inc. (ALXN) stock price, quote ... Find the latest Alexion Pharmaceuticals, Inc. (ALXN) stock quote, history, news and other vital information to help you with your stock trading and investing.

ALXN: Alexion Pharmaceuticals Inc - Stock Price, Quote and ... Get Alexion Pharmaceuticals Inc (ALXN:NASDAQ) real-time stock quotes, news and financial information from CNBC. Alexion Pharmaceuticals, Inc. Common Stock (ALXN) Analyst ... Alexion Pharmaceuticals, Inc. Common Stock (ALXN) Analyst Research. ALXN Analyst Ratings. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00.

Company Name: Alexion Pharmaceuticals Inc., Stock Symbol: ALXN, Industry: Biotechs, Total Posts: 152, Last Post: 1/25/2020 5:22:03 PM.

Share. Stock. ALXN. Price as of: Mar 26, 10:00 PM. $90.35 +0.42 +0.47% Alexion Pharmaceuticals, Inc. (ALXN). Stock Dividend Yield & Stock Price History. Dec 26, 2019 Alexion Pharmaceuticals, Inc. (ALXN) stock has risen 10.99% over the last 12 months, and the average rating from Wall Street analysts is a  analysis, current ALXN quote, charts, and historical prices for Alexion Pharmaceuticals stock. Alexion Pharmaceuticals, Inc. Is Researching a Turnaround. Alexion Pharmaceuticals (NASDAQ:ALXN) Share Price and News. Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company engaged in the   View the latest ALXN stock quote and chart on MSN Money. Dive deeper with interactive charts and top stories of ALEXION PHARMACEUTICALS, INC.. Company Name: Alexion Pharmaceuticals Inc., Stock Symbol: ALXN, Industry: Biotechs, Total Posts: 152, Last Post: 1/25/2020 5:22:03 PM. Mar 17, 2020 On 16-03-2020 (Monday), ALXN stock construct a change of -6.07 in a total of its share price and finished its trading at 75.56. Profitability Ratios ( 

Adjusted Profits And Stock Prices of AcelRx ...

Alexion Pharmaceuticals stock price target raised to $165 from $133 at Instinet MarketWatch. Wednesday, January 08, 2020. 08:22 AM ET. Alexion Pharmaceuticals stock price target cut to $161 from $170 at Raymond James MarketWatch. Tuesday, January 07, 2020. 09:25 AM ET. Apellis stock soars on positive data for potential Soliris competitor ALXN Alexion Pharmaceuticals, Inc. Stock Quote Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and …

On eToro, you can buy $ALXN or other stocks and pay ZERO commission! Follow Alexion Pharmaceuticals Inc share price and get more information. Terms apply.

NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have  Stock Quote. NASDAQ: ALXN. $89.77. Apr 3, 2020 4:00 PM EDT. Change; -0.58 (-0.64%): Volume; 1,693,879: Today's Open; $91.15: Previous Close; $90.35.

Alexion Pharmaceuticals Inc. is an American pharmaceutical company best known for its The price represented more than a 135% premium over Synageva's market cap at the time. As of 2017 Alexion Pharmaceuticals shares are mainly held by institutional investors (Fidelity Investments, T. Rowe Price, BlackRock and 

ALXN Alexion Pharmaceuticals, Inc. Stock Quote Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and … Alexion Pharmaceuticals Stock Quote. ALXN - Stock Price ...

Alexion Pharmaceuticals Alexion is a global biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders. Update Read about our response to COVID-19.